Florida A&M University (FAMU) has received funding from the National Institutes of Health (NIH) Research Centers in Minority Institutions (RCMI) Program since 1985. The RCMI funding has been a cornerstone and instrumental in expanding research capabilities through supporting development of infrastructure, establishment and enhancement of basic and animal research laboratories, support of pilot projects and facilitation of translational research. This support has increased the number of research activities within the College and resulted in increased continuation of funded contracts, grants, publications and presentations. Researchers at FAMU College of Pharmacy and Pharmaceutical Sciences (FAMU COPPS) have made contributions to the research community in the areas of neuroscience, drug discovery, drug delivery and molecular biology with a gradual and steady incline in quality of research publications with high impact factor, parallel to updated molecular biology facilities and concomitant to the development of novel ideas, therapeutic strategies and issued patents with potential to commercialize. The RCMI support has enhanced faculty members’ grantsmanship in competing and securing extramural funding at FAMU and in particular the FAMU COPPS.
The major goal of the RCMI program is to support the development and expansion of a strong infrastructure for conducting multidisciplinary collaborative research studies through the establishment of four synergist cores with mutual goals which are to enable research on diseases affecting minority groups especially African Americans. The overarching objective of the RCMI program is to have a unified center that focuses on the development of methodologies, technologies, innovative tools and subsequent discoveries that ultimately provide benefit to the health and well-being of disadvantaged populations groups. Research investigators in the RCMI center will be focusing their efforts using unique approaches and synergistic collaborations with diversification of techniques in areas including DNA sequencing, genetic engineering/ recombinant technologies, epigenetics, RNA expression transcription/splicing and translation/ post-translational modification of proteins through proteomics, molecular modeling and drug design with supportive microarray technologies. These objectives are to enhance the current University and College research infrastructure, enhance existing faculty member’s grantsmanship, and develop new and junior faculty member’s research capabilities by promoting basic and translational research that addresses health disparities.
Karam F.A. Soliman, PhD
Distinguished Professor, Basic Pharmaceutical Sciences